Takahashi Hitoshi, Sugita Takio, Higuchi Hisashi, Shimizu Tetsuo
Department of Neuropsychiatry, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Hum Psychopharmacol. 2002 Mar;17(2):95-8. doi: 10.1002/hup.367.
We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone. A total of 30 patients completed the open trial over a 12-week period during which fluvoxamine was added to risperidone. The result from the positive and negative syndrome scale (PANSS) and Simpson-Angus extrapyramidal effects (S-A) scale were examined at baseline, 1, 2, 4, 8 and 12 weeks of treatment. There were no significant differences in PANSS positive, negative and general psychopathology scores, or in S-A scale scores at any point during the treatment. These results suggest that fluvoxamine appears to be ineffective in augmenting the risperidone treatment response in chronic schizophrenic patients. Further controlled trials will be needed to confirm this observation.
我们研究了用氟伏沙明增强利培酮治疗慢性精神分裂症残留阳性和阴性症状的疗效及安全性，这些患者对利培酮治疗反应不完全。共有30例患者在12周的开放试验中完成研究，在此期间氟伏沙明被添加到利培酮治疗中。在治疗的基线、第1、2、4、8和12周时，对阳性和阴性症状量表（PANSS）及辛普森-安格斯锥体外系反应（S-A）量表的结果进行了检查。在治疗期间的任何时间点，PANSS阳性、阴性及一般精神病理学评分或S-A量表评分均无显著差异。这些结果表明，氟伏沙明在增强慢性精神分裂症患者对利培酮的治疗反应方面似乎无效。需要进一步的对照试验来证实这一观察结果。
